This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Gaining perspective on Biogen's Tofersen (BIIB067) recently approved for the treatment of ALS
Ticker(s): BIIBWho's the expert?
Institution: University of Buffalo
- Clinical Associate Professor of Neurology at the University of Buffalo.
- Research is focused on several studies that address illnesses such as Guillain-Barre syndrome, myasthenia gravis and polyneuropathy.
- Basic science research is focused on pathophysiology of inherited neuropathies, which are known collectively as Charcot-Marie-Tooth (CMT) disease, with the goal of better understanding the underlying cause or mechanisms of these diseases.
Interview GoalTo better understand the potential of Tofersen following the release of the VALOR clinical trial data, and its recent FDA approval
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
